INNOVATION ZONE

National Science Foundation Small Business Innovation Research Companies @ 2014 BIO International Convention

DRUG DISCOVERY

CARMOT THERAPEUTICS INC.



Applies its proprietary Chemotype Evolution technology to discover novel drug candidates that target pathways related to metabolic disease, oncology and inflammation.

Dave Jobes | djobes@carmot.us


LONGEVITY BIOTECH INC.



Developing a new class of therapeutics based on the Hybridtide platform technology across therapeutic areas. Hybridtides blend biological specificity with small molecule stability resulting in stable yet potent drug candidates.

Scott Shandler | scott@longevitybiotech.com


PRIVO TECHNOLOGIES



Develops new classes of targeted treatments, such as chemotherapy drugs, radiation sensitizers and radiation protectors and mitigators, designed to be delivered through mucous membranes in the mouth or elsewhere.

Manijeh Goldberg | mgoldberg@privotechnologies.com

PROTABIT LLC



Focuses on developing and applying protein design software tools for engineering new and improved proteins. The Protabit software platform integrates computational approaches with protein design, allowing users to tailor methodology for specific design goals.

Barry Olafson | barry.olafson@protabit.com

TYMORA ANALYTICAL OPERATIONS



Provides new research products and reagents to R&D organizations within the life sciences market. Tymora has developed technologies for the analysis of protein phosphorylation that relate to the onset of cancer and other diseases.

Anton Iliuk | anton.iliuk@tymora-analytical.com

TREATMENTS

ACTUATED MEDICAL INC.



Focuses on minimally invasive instruments for clearing occlusions, penetrating bone and tissue, and enabling the emerging MRI–guided surgical procedure industry.

Roger Bagwell | roger.bagwell@actuatedmedical.com

ARYTHA BIOSCIENCES



Develops nano-sponges to locate toxins in the bloodstream. The sponges are made of red blood cell membranes and serve as a synthetic decoy to capture and neutralize toxins regardless of their molecular structures.

Che-Ming Hu | chu@arythabio.com

GIGAGEN INC.



Uses microfluidics, bioinformatics and next-generation sequencing to mine complete B cell repertoires for antibodies that are safer, more effective and more biologically relevant. GigaGen seeks to empower its biopharma R&D customers to discover the world's best prophylactic and therapeutic monoclonal antibodies using natural genetic diversity.

David Johnson | djohnson@gigagen.com


PURACATH MEDICAL



Works to improve dialysis patients' quality of life through the development of a disinfection process for peritoneal dialysis catheter interfaces.

Julia Rasooly | julia@puracath.com


SENSULIN LLC



Developing a 24-hour glucose-responsive insulin that could eliminate the four-to-seven daily required injections for Type I diabetes patients and offer better compliance for Type II patients.

Michael Moradi-Araghi | mikemoradi@gmail.com

THERMALLY TARGETED THERAPEUTICS INC.




Tests the application of a heat-responsive biopolymer to deliver breast cancer therapy and to prevent disease recurrence.

Drazen Raucher | draucher@umc.edu

DIAGNOSTICS AND MONITORING

ADM DIAGNOSTICS LLC



Provides neuroimaging studies and data analysis to pharmaceutical companies, emphasizing central nervous system disorders. ADM Diagnostics has developed approaches for the collection, quality control, and analysis of image data to make results more reliable and easier to understand.

Ana Lukic | alukic@admdx.com

ALPHA UNIVERSE LLC



Develops new approaches for the detection and identification of biothreats and other infectious disease-related agents. Alpha Universe LLC also provides personal information preservation services and assistance in secure analysis of preserved information.

Alexey Zdanovsky | alexeyzd@alphayou.com

APPLIED BIOSENSORS LLC



Provides single-use sensors for continuous monitoring of multiple biochemicals (pH, glucose, osmolality, etc.) primarily for biomanufacturing industry. The technology is applicable to several markets, including biomedical research, human metabolic monitoring, and water quality management.

Prashant Tathireddy | info@appliedbiosensors.com





Enables high-throughput, label-free analysis of cells' morphological and structural properties, unlocking a new class of reliable, single-cell biomarkers. Using this approach to rapidly interrogate clinical fluid samples, target cells may be identified in oncology, infectious disease, and regenerative medicine applications.

Daniel Gossett | daniel.gossett@cytovale.com

GENENDEAVOUR LLC



Develops genetic testing products using autoligation chain reaction, an enabling nucleic acid amplification technology that requires no nucleotides or enzymes.

Ricardo Mancebo | genendeavor@bioideas.com

NOVASCAN LLC



Developed a technology that detects cancer real-time in human tissue. The technology has already been applied to breast cancer. Other potential targets are skin cancer and thyroid cancer.

William Gregory | wdguwm@aol.com

PHASIQ INC.



Commercializing a reliable, sensitive and accurate test for disease diagnosis and clinical trials. The test detects and measures proteins in biological fluids such as plasma, urine and serum. It can be read using existing laboratory equipment, allowing for easy adoption in academic labs and pharmaceutical companies.

Sachin Shah | sachin@phasiqinc.com

ENGINEERING BIOLOGY

GINKGO BIOWORKS



Engineers organisms for the cost-effective production of specialty chemicals and licenses them to leading companies.

Effendi Leonard | eleonard@ginkgobioworks.com



MANGO MATERIALS



Produces biodegradable plastics from methane that are economically and functionally competitive with conventional oil-based plastics.

Molly Morse | molly@mangomaterials.com

PHYLLOTECH LLC



Develops new techniques for the sustainable production of high-value proteins in plants and the environmentally friendly control of agricultural pathogens.

Ryan Shepherd | ryan.shepherd@phyllotech.com

TRILLIUM FIBERFUELS INC.



Creates technology focused on the conversion of cellulosic biomass to ethanol and higher-value products. Trillium's fermentation-compatible xylose isomerase enzyme enables simultaneous isomerization and fermentation of xylose to ethanol using conventional yeast.

Stephen Potochnik | steve@trilliumfiberfuels.com



FOR MORE INFORMATION CONTACT:

Sarah Bates | 703.292.7738 | sabates@nsf.gov

